CATX FY2024 EPS Estimate Raised by Cantor Fitzgerald

Perspective Therapeutics, Inc. (NYSE:CATX) – Stock analysts at Cantor Fitzgerald lifted their FY2024 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of ($0.90) for the year, up from their previous forecast of ($0.95). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.86) per share.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million for the quarter.

Other research analysts have also issued reports about the stock. Bank of America assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective on the stock. Royal Bank of Canada lowered their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. UBS Group began coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Oppenheimer reiterated an “outperform” rating and set a $22.00 target price on shares of Perspective Therapeutics in a research note on Friday, October 11th. Finally, Wedbush restated an “outperform” rating and issued a $20.00 price target on shares of Perspective Therapeutics in a research note on Thursday, October 24th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $21.57.

Perspective Therapeutics Trading Down 11.8 %

NYSE:CATX opened at $6.95 on Monday. Perspective Therapeutics has a twelve month low of $2.28 and a twelve month high of $19.05. The business’s 50 day moving average is $12.55.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bleakley Financial Group LLC bought a new stake in Perspective Therapeutics during the first quarter valued at $40,000. nVerses Capital LLC acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at about $57,000. US Bancorp DE boosted its position in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics during the second quarter worth approximately $117,000. Finally, Point72 DIFC Ltd bought a new stake in Perspective Therapeutics in the second quarter worth approximately $118,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.